Doron Gothelf1, Amanda J Law2, Amos Frisch3, Jingshan Chen4, Omer Zarchi1, Elena Michaelovsky5, Renee Ren-Patterson4, Barbara K Lipska4, Miri Carmel5, Bhaskar Kolachana4, Abraham Weizman3, Daniel R Weinberger6. 1. Behavioral Neurogenetics Center, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 2. Departments of Psychiatry and Cell and Developmental Biology, School of Medicine, University of Colorado, Aurora, Colorado; Clinical Brain Disorders Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland. 3. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; The Felsenstein Medical Research Center, Petah Tiqwa, Israel. 4. Clinical Brain Disorders Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland. 5. The Felsenstein Medical Research Center, Petah Tiqwa, Israel. 6. Clinical Brain Disorders Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland; Lieber Institute for Brain Development, Johns Hopkins University Medical Campus; Departments of Psychiatry, Neurology, and Neuroscience and the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: drweinberger@libd.org.
Abstract
BACKGROUND: 22q11.2 deletion syndrome (22q11.2DS) is the most common genetic syndrome associated with schizophrenia. The catechol-O-methyltransferase (COMT) gene is located in the obligatory deletion region, and possible associations between COMT variants and neuropsychiatric manifestations in 22q11.2DS have been reported. The purpose of the current study was to evaluate the effect of COMT hemizygosity and molecular haplotypes on gene expression and enzyme activity and its association with psychotic symptoms in 22q11.2DS. METHODS: Lymphoblast samples were drawn from 53 individuals with 22q11.2DS and 16 typically developing control subjects. We measured COMT messenger (m)RNA and protein expression and enzyme activity using standard procedures. The presence of a psychotic disorder and cognitive deficits were also evaluated using structured testing. RESULTS: There was an approximately 50% reduction in COMT mRNA, protein, and enzyme activity levels in 22q11.2DS samples. Haplotype analysis revealed clear phenotypic differences between various Val-containing haplotypes on COMT-3' untranslated region extended mRNA, soluble COMT and membrane-bound proteins, and enzyme activity. The G variant of rs165599, a 3' untranslated region single nucleotide polymorphism, was associated with low levels of COMT expression and with the presence of psychosis and lower performance IQ scores in our 22q11.2DS sample. Finally, we demonstrate that the COMT rs74745580 "T" mutation is associated with absent soluble COMT expression and very low COMT activity in two 22q11.2DS individuals. CONCLUSIONS: Our findings confirm a robust effect of COMT hemizygosity on COMT activity and show complex interactions of variants within the COMT gene that influence COMT biology and confound conclusions based on associations with the Val158Met genotype alone.
BACKGROUND: 22q11.2 deletion syndrome (22q11.2DS) is the most common genetic syndrome associated with schizophrenia. The catechol-O-methyltransferase (COMT) gene is located in the obligatory deletion region, and possible associations between COMT variants and neuropsychiatric manifestations in 22q11.2DS have been reported. The purpose of the current study was to evaluate the effect of COMT hemizygosity and molecular haplotypes on gene expression and enzyme activity and its association with psychotic symptoms in 22q11.2DS. METHODS: Lymphoblast samples were drawn from 53 individuals with 22q11.2DS and 16 typically developing control subjects. We measured COMT messenger (m)RNA and protein expression and enzyme activity using standard procedures. The presence of a psychotic disorder and cognitive deficits were also evaluated using structured testing. RESULTS: There was an approximately 50% reduction in COMT mRNA, protein, and enzyme activity levels in 22q11.2DS samples. Haplotype analysis revealed clear phenotypic differences between various Val-containing haplotypes on COMT-3' untranslated region extended mRNA, soluble COMT and membrane-bound proteins, and enzyme activity. The G variant of rs165599, a 3' untranslated region single nucleotide polymorphism, was associated with low levels of COMT expression and with the presence of psychosis and lower performance IQ scores in our 22q11.2DS sample. Finally, we demonstrate that the COMTrs74745580 "T" mutation is associated with absent soluble COMT expression and very low COMT activity in two 22q11.2DS individuals. CONCLUSIONS: Our findings confirm a robust effect of COMT hemizygosity on COMT activity and show complex interactions of variants within the COMT gene that influence COMT biology and confound conclusions based on associations with the Val158Met genotype alone.
Authors: Sagiv Shifman; Michal Bronstein; Meira Sternfeld; Anne Pisanté-Shalom; Efrat Lev-Lehman; Avraham Weizman; Ilya Reznik; Baruch Spivak; Nimrod Grisaru; Leon Karp; Richard Schiffer; Moshe Kotler; Rael D Strous; Marnina Swartz-Vanetik; Haim Y Knobler; Eilat Shinar; Jacques S Beckmann; Benjamin Yakir; Neil Risch; Naomi B Zak; Ariel Darvasi Journal: Am J Hum Genet Date: 2002-10-25 Impact factor: 11.025
Authors: Jennifer S Ho; Petya D Radoeva; Maria Jalbrzikowski; Carolyn Chow; Jessica Hopkins; Wen-Ching Tran; Ami Mehta; Nicole Enrique; Chelsea Gilbert; Kevin M Antshel; Wanda Fremont; Wendy R Kates; Carrie E Bearden Journal: Autism Res Date: 2012-09-07 Impact factor: 5.216
Authors: Jingshan Chen; Barbara K Lipska; Nader Halim; Quang D Ma; Mitsuyuki Matsumoto; Samer Melhem; Bhaskar S Kolachana; Thomas M Hyde; Mary M Herman; Jose Apud; Michael F Egan; Joel E Kleinman; Daniel R Weinberger Journal: Am J Hum Genet Date: 2004-09-27 Impact factor: 11.025
Authors: Rael D Strous; Karen A Nolan; Raya Lapidus; Libna Diaz; Takuya Saito; Herbert M Lachman Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2003-07-01 Impact factor: 3.568
Authors: Janneke R Zinkstok; Erik Boot; Anne S Bassett; Noboru Hiroi; Nancy J Butcher; Claudia Vingerhoets; Jacob A S Vorstman; Therese A M J van Amelsvoort Journal: Lancet Psychiatry Date: 2019-08-05 Impact factor: 27.083
Authors: Sunny X Tang; Tyler M Moore; Monica E Calkins; James J Yi; Adam Savitt; Christian G Kohler; Margaret C Souders; Elaine H Zackai; Donna M McDonald-McGinn; Beverly S Emanuel; Ruben C Gur; Raquel E Gur Journal: Biol Psychiatry Date: 2016-09-08 Impact factor: 13.382
Authors: Jiaojiao Li; Chunxiao Sun; Wenwen Cai; Jing Li; Barry P Rosen; Jian Chen Journal: Mutat Res Rev Mutat Res Date: 2021-10-07 Impact factor: 7.015
Authors: Sara Sannino; Alessandro Gozzi; Antonio Cerasa; Fabrizio Piras; Diego Scheggia; Francesca Managò; Mario Damiano; Alberto Galbusera; Lucy C Erickson; Davide De Pietri Tonelli; Angelo Bifone; Sotirios A Tsaftaris; Carlo Caltagirone; Daniel R Weinberger; Gianfranco Spalletta; Francesco Papaleo Journal: Cereb Cortex Date: 2014-03-21 Impact factor: 5.357
Authors: Goran Šimić; Mladenka Tkalčić; Vana Vukić; Damir Mulc; Ena Španić; Marina Šagud; Francisco E Olucha-Bordonau; Mario Vukšić; Patrick R Hof Journal: Biomolecules Date: 2021-05-31
Authors: Alistair T Pagnamenta; Malcolm F Howard; Eva Wisniewski; Niko Popitsch; Samantha J L Knight; David A Keays; Gerardine Quaghebeur; Helen Cox; Phillip Cox; Tamas Balla; Jenny C Taylor; Usha Kini Journal: Hum Mol Genet Date: 2015-04-08 Impact factor: 6.150
Authors: Maria Jalbrzikowski; Maria T Lazaro; Fuying Gao; Alden Huang; Carolyn Chow; Daniel H Geschwind; Giovanni Coppola; Carrie E Bearden Journal: PLoS One Date: 2015-07-22 Impact factor: 3.240